Indacaterol vs long‐acting beta2‐agonist alone
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
- Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 2708 participantsHigh